Positives

• Trial participants on the 9 mg dose lost an average of 11.7% of body weight by week 12 versus 1.8% on placebo, with HbA1c reductions of up to 2.15% in diabetic participants Lancet eClinicalMedicine.
  
  
• In the head-to-head DREAMS-3 trial, patients on mazdutide lost more weight than those on semaglutide, suggesting the added glucagon agonism delivers a meaningful edge for some users Nature.
  
  

Negatives

• Trial participants most commonly reported diarrhea, decreased appetite, nausea, abdominal distension, and vomiting, mirroring other GLP-1/glucagon agonists PMC.
  
  
• An adolescent case report on dose-escalated mazdutide noted upper-respiratory infections and urinary tract infections during the titration period Frontiers.
  
  

Hurdles & Side Effects

• Mazdutide is approved only in China through Innovent, leaving Western patients with no legal pharmacy pathway and no insurance coverage for off-label trials Nature.
  
  
• Because dual glucagon agonism increases hepatic energy expenditure, patients with thinner builds or post-viral cachexia would need close monitoring to avoid unintended weight loss PMC.